CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
8.70
-0.40 (-4.40%)
May 13, 2025, 4:00 PM - Market closed
CervoMed Revenue
CervoMed had revenue of $1.92M in the quarter ending March 31, 2025, a decrease of -18.31%. This brings the company's revenue in the last twelve months to $9.31M, up 15.14% year-over-year. In the year 2024, CervoMed had annual revenue of $9.74M with 36.29% growth.
Revenue (ttm)
$9.31M
Revenue Growth
+15.14%
P/S Ratio
8.14
Revenue / Employee
$620,548
Employees
15
Market Cap
75.71M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.74M | 2.59M | 36.29% |
Dec 31, 2023 | 7.14M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCRVO News
- 1 day ago - CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 6 weeks ago - Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
- 7 weeks ago - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™) - GlobeNewsWire
- 7 weeks ago - CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats - Seeking Alpha
- 2 months ago - CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies - GlobeNewsWire
- 3 months ago - CervoMed to Present at the 8th International Lewy Body Dementia Conference - GlobeNewsWire
- 5 months ago - CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 months ago - CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Benzinga